William Lewis Sells 10,699 Shares of Insmed (NASDAQ:INSM) Stock

Insmed, Inc. (NASDAQ:INSM) CEO William Lewis sold 10,699 shares of the stock in a transaction dated Thursday, March 19th. The stock was sold at an average price of $143.52, for a total value of $1,535,520.48. Following the transaction, the chief executive officer owned 301,185 shares of the company’s stock, valued at approximately $43,226,071.20. The trade was a 3.43% decrease in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which is available through this link.

William Lewis also recently made the following trade(s):

• On Thursday, March 5th, William Lewis sold 10,699 shares of Insmed stock. The stock was sold at an average price of $146.03, for a total value of $1,562,374.97.
• On Thursday, February 19th, William Lewis sold 10,699 shares of Insmed stock. The stock was sold at an average price of $150.97, for a total transaction of $1,615,228.03.
• On Monday, February 9th, William Lewis sold 13,396 shares of Insmed stock. The stock was sold at an average price of $147.79, for a total transaction of $1,979,794.84.
• On Tuesday, February 3rd, William Lewis sold 3,009 shares of Insmed stock. The shares were sold at an average price of $156.34, for a total transaction of $470,427.06.
• On Tuesday, January 20th, William Lewis sold 10,699 shares of Insmed stock. The stock was sold at an average price of $158.93, for a total transaction of $1,700,392.07.
• On Monday, January 12th, William Lewis sold 19,215 shares of Insmed stock. The stock was sold at an average price of $169.00, for a total transaction of $3,247,335.00.
• On Thursday, January 8th, William Lewis sold 3,223 shares of Insmed stock. The shares were sold at an average price of $174.17, for a total transaction of $561,349.91.
• On Wednesday, January 7th, William Lewis sold 2,357 shares of Insmed stock. The shares were sold at an average price of $175.07, for a total transaction of $412,639.99.
• On Tuesday, January 6th, William Lewis sold 4,096 shares of Insmed stock. The stock was sold at an average price of $173.33, for a total transaction of $709,959.68.

Insmed Trading Down 5.6%

Insmed stock opened at $136.00 on Friday. The firm has a 50-day moving average of $151.95 and a 200-day moving average of $166.11. Insmed, Inc. has a one year low of $60.40 and a one year high of $212.75. The company has a debt-to-equity ratio of 0.76, a current ratio of 3.83 and a quick ratio of 3.54. The company has a market cap of $29.31 billion, a price-to-earnings ratio of -21.22 and a beta of 1.13.

Insmed (NASDAQ:INSM) last released its earnings results on Thursday, February 19th. The biopharmaceutical company reported ($1.54) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($1.07) by ($0.47). Insmed had a negative net margin of 210.54% and a negative return on equity of 168.36%. The company had revenue of $263.84 million during the quarter, compared to analyst estimates of $263.97 million. During the same period in the prior year, the firm posted ($1.32) EPS. Insmed’s revenue was up 152.6% compared to the same quarter last year. On average, equities analysts expect that Insmed, Inc. will post -4.56 earnings per share for the current fiscal year.

Institutional Inflows and Outflows

Institutional investors have recently made changes to their positions in the business. CIBC Private Wealth Group LLC lifted its holdings in Insmed by 42.1% during the 3rd quarter. CIBC Private Wealth Group LLC now owns 179 shares of the biopharmaceutical company’s stock valued at $26,000 after purchasing an additional 53 shares during the last quarter. Kingsview Wealth Management LLC raised its position in shares of Insmed by 2.7% in the third quarter. Kingsview Wealth Management LLC now owns 2,321 shares of the biopharmaceutical company’s stock valued at $334,000 after purchasing an additional 60 shares during the period. Choreo LLC lifted its stake in shares of Insmed by 2.9% during the 3rd quarter. Choreo LLC now owns 2,319 shares of the biopharmaceutical company’s stock worth $334,000 after buying an additional 65 shares during the last quarter. EverSource Wealth Advisors LLC boosted its holdings in shares of Insmed by 10.2% during the 4th quarter. EverSource Wealth Advisors LLC now owns 747 shares of the biopharmaceutical company’s stock worth $130,000 after buying an additional 69 shares during the period. Finally, ORG Partners LLC boosted its holdings in shares of Insmed by 12.7% during the 4th quarter. ORG Partners LLC now owns 657 shares of the biopharmaceutical company’s stock worth $114,000 after buying an additional 74 shares during the period.

Analyst Ratings Changes

A number of brokerages have recently issued reports on INSM. Wolfe Research set a $167.00 price objective on Insmed and gave the stock an “outperform” rating in a research note on Thursday, December 18th. UBS Group decreased their target price on shares of Insmed from $223.00 to $215.00 and set a “buy” rating for the company in a research note on Tuesday, January 6th. Weiss Ratings restated a “sell (d-)” rating on shares of Insmed in a report on Thursday, January 22nd. Guggenheim cut their price target on shares of Insmed from $230.00 to $221.00 and set a “buy” rating for the company in a research note on Thursday, December 18th. Finally, Royal Bank Of Canada lifted their price objective on shares of Insmed from $197.00 to $200.00 and gave the company an “outperform” rating in a research report on Wednesday, January 21st. Three research analysts have rated the stock with a Strong Buy rating, nineteen have given a Buy rating, one has given a Hold rating and one has issued a Sell rating to the company’s stock. Based on data from MarketBeat, the stock currently has an average rating of “Buy” and a consensus price target of $205.57.

Insmed Company Profile

Insmed Incorporated is a biopharmaceutical company focused on developing and commercializing therapies for patients with rare and serious diseases, with a particular emphasis on difficult-to-treat pulmonary infections. Headquartered in Bridgewater, New Jersey, the company concentrates its research and development efforts on targeted drug delivery technologies and novel formulations intended to improve clinical outcomes for patients who have limited treatment options.

The company’s principal marketed product is ARIKAYCE (amikacin liposome inhalation suspension), an inhaled liposomal formulation of the antibiotic amikacin that is approved by the U.S.